Abstract
CsA induced prolonged remissions in adults with IDDM. We report on our experience in children treated with 2 different CsA dosages. CsA was given orally, for 6 mth targetting a CsA trough plasma level either of 100 ng/ml (group I - n=14) or 200 ng/ml (group II - n=14). Both groups were compared to 12 “control” cases of comparable glycemic control receiving no CsA. Results were evaluated on insulin requirement and glucagon stimulated C-peptide. In group I, no major side effects were observed. In group II, blood pressure was elevated in 6. Creatinine levels increased (82 ± 12 at 6 mth, vs 62 ± 10 μmol/1-ns-). All the side effects have been reversible. In group I, 5 cases underwent a total insulin remission for 1-4 mth, 3 cases no remission at all, and 6 a partial remission. In group II so far (n=7) at 6 mth, 4 cases underwent a total remission for 2-9 mth and 3 a partial remission. Stimulated C-peptide was higher in group II, compared to group I (273 ± 1.4 vs 1.84 ± 1.3 ng /ml respectively at 6 mth). In group II, both basal and stimulated C-peptide were higher in ran insulin treated cases from the 3rd mth on. In conclusion : In this open trial, CsA has a positive effect on the remission period. A dose effect relationship was demonstrated. Benefits of a high CsA dosage,inducing a sustained remission, might be balanced by noticeable side effects.
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call